Brexit Finally Here But Uncertainty Not Over For Biopharma
Doubts Persist On Regulatory Alignment And Migration
A free trade deal needs to be negotiated in record time and UK life sciences must face up to diverging from the EU.
You may also be interested in...
Moderna has unveiled plans to develop a new booster vaccine, tweaked to meet the threat posed by the South African strain.
Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.
Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.